Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
Browsing Tag: Phase 3 PaTHway
Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...